Our purpose is to realize the promise of viral medicines, thereby extending the horizons of human healthcare.
We pioneered a new product category of Viral Sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. Customized VSE formulations optimize research processes and enhance production. VSEs help bring your treatments to patients on an accelerated timeline.
Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Jean-Simon Diallo at the Ottawa Hospital Research Institute.
Dr. Diallo was investigating novel oncolytic viral therapies (OVTs) and recognized the need for VSEs to enhance the effectiveness of OVTs. After researching and developing VSEs in the OVT space, Dr. Diallo recognized how broadly applicable their attributes would be in other areas like gene therapy and vaccine production. Recent influenza outbreaks and the COVID-19 pandemic highlight the need for scalability in the production of vaccines. Virica has the products and experience to combat these challenges.
Biotechnology Industry Alliances
Virica supports the biotechnology industry. Here is a snapshot of organizations with whom we share knowledge by attending meetings or giving presentations.
Virica is a member of BIOTECanada, an association building a climate for biotechnology firms to succeed in today’s hyper-competitive economy. Visit the website.
Alliance of Regenerative Medicine
Virica is a member of Alliance of Regenerative Medicine. This association supports the development of safe and effective regenerative medicines and advanced therapies worldwide. Visit the website.